How many clinical trials are there for Egfr Pacc?

PlainTrial tracks 1 US clinical trials for Egfr Pacc, of which 1 are currently recruiting.

Which interventions appear most often on Egfr Pacc trial records?

EGFR-TKI inhibitor based on investigator's choice is the most-linked intervention name on Egfr Pacc records (1 trial links), followed by Firmonertinib. Names are sponsor-reported on ClinicalTrials.gov.

How do I find a recruiting trial for Egfr Pacc?

Use the trial list filtered by Recruiting status, or visit the trial finder to search by condition and state. Always discuss with your healthcare provider.

Is this data current?

Data is from ClinicalTrials.gov. Trial status may have changed. Always verify at ClinicalTrials.gov before making participation decisions.

Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Egfr Pacc: later-stage trial registry

Compiled by PlainTrial · August 8, 2026

1 of 1 indexed Egfr Pacc trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Egfr Pacc: 1 US clinical trial tracked, 1 recruiting.

Egfr Pacc is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is ArriVent BioPharma, running 1 of these trials.

Enrollment posture brief

Registry condition egfr-pacc

Volume-matched condition peers

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Open-enrollment share among volume-matched conditions near Egfr Pacc

Egfr Pacc lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Egfr Pacc on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

Egfr Pacc is recruiting above its size-band peers.

1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Open and recent trials

1 total, page 1 of 1

RECRUITING Phase 3 480 participants

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

ArriVent BioPharma

NCT07185997

Phase Distribution

Phase	Trial count
Phase 3	1

Top Sponsors

ArriVent BioPharma 1 trials

Named interventions

Most-linked intervention names on Egfr Pacc records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

EGFR-TKI inhibitor based on investigator's choice Drug

1 trials

Firmonertinib Drug

1 trials

US sites by state

Facility locations filed on Egfr Pacc trials. A trial with sites in several states counts in each.

Virginia 1 trials

Texas 1 trials

New York 1 trials

California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Egfr Pacc page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

1 Egfr Pacc trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
ArriVent BioPharma sponsors the most Egfr Pacc trials on record, review their full trial history before evaluating a specific study. See ArriVent BioPharma's trials
Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Egfr Pacc condition card totals 1 registered trials; most-linked intervention EGFR-TKI inhibitor based on investigator's choice; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.